鼠李糖乳杆菌HN001菌株水平快速定量方法的建立及应用

目的 应用实时荧光定量聚合酶链式反应(real-timefluorescencequantitativepolymerasechainreaction,qPCR),建立鼠李糖乳杆菌HN001菌株水平的快速定量检测方法。方法 通过比对鼠李糖乳杆菌HN001的近缘菌株的基因组,筛选出鼠李糖乳杆菌HN001菌株水平的特异基因,以菌株水平的特异基因为靶标设计引物及探针,优化反应体系和条件,建立鼠李糖乳杆菌HN001株水平的q PCR检测方法。对方法的特异性、灵敏度、检出限进行验证,并采用已建立的q PCR方法进行模拟添加样品和实际样品的检测。结果 所建立的方法特异性强,与近缘菌株无交叉反应,鼠李糖乳杆菌HN001纯培养液检出限为102 CFU/mL,灵敏度可达到650 copies/μL,可在2h内完成样品检测。对模拟添加样品以及实际样品检测中q PCR和平板计数法结果的对数值进行显著性分析检验,两种方法的测定值结果均无显著性差异(P>0.05)。结论 本研究建立的q PCR检测方法可有效应用于益生菌产品中鼠李糖乳杆菌HN001菌株水平定量检测,具有快速、灵敏、准确的特点。     

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance

Androgen receptor targeted therapies for prostate cancer have serious limitations in advanced stages of the disease. While resistance to the FDA-approved enzalutamide is extensively documented, novel therapies based on epichlorohydrin scaffolds (EPI) are currently in clinical trials, but display suboptimal pharmacokinetics. Herein, we report the synthesis and biological characterisation of a novel class of compounds designed through covalently linking enzalutamide and EPI-001 through various triazole based linkers. The compounds display an 18 to 53 fold improvement in the cell killing potency towards C4-2b prostate cancer (PCa) cells compared to the gold standards of therapy, enzalutamide and EPI-001. The most promising compounds were proven to exhibit their toxicity exclusively through androgen receptor (AR) mediated pathways. This work sets the basis for the first class of hybrid AR inhibitors which successfully combine two drug moieties – EPI-001 and enzalutamide – into the same molecule.